Evidence map›Paper›PMID 22360269›Full record

ArticleThe Biochemical journal2012

MEF2 is regulated by CaMKIIδ2 and a HDAC4-HDAC5 heterodimer in vascular smooth muscle cells.

Roman Ginnan, Li Yan Sun, John J Schwarz, Harold A Singer

Open access · greenAbstract read
In one paragraph

Article in The Biochemical journal, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 54 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. HDAC4 Inhibitors as Antivascular Senescence Therapeutics.Oxidative medicine and cellular longevity · 2022
    Review
  9. Article
  10. CaMKIIδ is upregulated by pro-inflammatory cytokine IL-6 in a JAK/STAT3-dependent manner to promote angiogenesis.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2021
    Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Roman GinnanCenter for Cardiovascular Sciences, Albany Medical College, NY 12208, USA.
Li Yan Sun
John J Schwarz
Harold A Singer
Albany Medical Center Hospital · US

Funding

CALCIUM/CALMODULIN ACTIVATED KINIASES IN SMOOTH MUSCLER01HL049426 · NHLBI · WEIS CENTER FOR RESEARCH-GEISINGER CLINC · PI SINGER, HAROLD A · 1994 to 2019
$6.2M
Control of Vascular Cell Motility by CaMKIIR01HL092510 · NHLBI · ALBANY MEDICAL COLLEGE · PI SINGER, HAROLD A · 2010 to 2013
$1.6M
NHLBI NIH HHS R01 HL049426NHLBI NIH HHS R01 HL092510NHLBI NIH HHS R01-HL-092510NHLBI NIH HHS R01-HL-49426
6 · The paper itself

Abstract

VSMCs (vascular smooth muscle cells) dedifferentiate from the contractile to the synthetic phenotype in response to acute vascular diseases such as restenosis and chronic vascular diseases such as atherosclerosis, and contribute to growth of the neointima. We demonstrated previously that balloon catheter injury of rat carotid arteries resulted in increased expression of CaMKII (Ca(2+)/calmodulin-dependent protein kinase) IIδ(2) in the medial wall and the expanding neointima [House and Singer (2008) Arterioscler. Thromb. Vasc. Biol. 28, 441-447]. These findings led us to hypothesize that increased expression of CaMKIIδ(2) is a positive mediator of synthetic VSMCs. HDAC (histone deacetylase) 4 and HDAC5 function as transcriptional co-repressors and are regulated in a CaMKII-dependent manner. In the present paper, we report that endogenous HDAC4 and HDAC5 in VSMCs are activated in a Ca(2+)- and CaMKIIδ(2)-dependent manner. We show further that AngII (angiotensin II)- and PDGF (platelet-derived growth factor)-dependent phosphorylation of HDAC4 and HDAC5 is reduced when CaMKIIδ(2) expression is suppressed or CaMKIIδ(2) activity is attenuated. The transcriptional activator MEF2 (myocyte-enhancer factor 2) is an important determinant of VSMC phenotype and is regulated in an HDAC-dependent manner. In the present paper, we report that stimulation of VSMCs with ionomycin or AngII potentiates MEF2's ability to bind DNA and increases the expression of established MEF2 target genes Nur77 (nuclear receptor 77) (NR4A1) and MCP1 (monocyte chemotactic protein 1) (CCL2). Suppression of CaMKIIδ(2) attenuates increased MEF2 DNA-binding activity and up-regulation of Nur77 and MCP1. Finally, we show that HDAC5 is regulated by HDAC4 in VSMCs. Suppression of HDAC4 expression and activity prevents AngII- and PDGF-dependent phosphorylation of HDAC5. Taken together, these results illustrate a mechanism by which CaMKIIδ(2) mediates MEF2-dependent gene transcription in VSMCs through regulation of HDAC4 and HDAC5.

Indexed as

Angiotensin IIAnimalsAorta, ThoracicCalcium-Calmodulin-Dependent Protein Kinase Type 1Chemokine CCL2Histone DeacetylasesIsoenzymesMEF2 Transcription FactorsMuscle, Smooth, VascularMyocytes, Smooth MuscleMyogenic Regulatory FactorsNuclear Receptor Subfamily 4, Group A, Member 1Platelet-Derived Growth FactorProtein MultimerizationRatsRats, Sprague-DawleyAngiotensin IICalcium-Calmodulin-Dependent Protein Kinase Type 1Chemokine CCL2HDAC4 protein, ratHdac5 protein, ratHistone DeacetylasesIsoenzymesMEF2 Transcription FactorsMyogenic Regulatory FactorsNr4a1 protein, ratNuclear Receptor Subfamily 4, Group A, Member 1Platelet-Derived Growth Factor

Identifiers

PMID22360269
PMCPMC3632366
OpenAlexW2064272094

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.